This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biologics Selected By ARIAD To Be The Exclusive Specialty Pharmacy Provider For Iclusig (ponatinib)

Biologics, Inc., an integrated oncology services company, is pleased to announce that it has been selected by ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) to be the sole specialty pharmacy provider of Iclusig ® (ponatinib) and manager of its Patient Access and Support Services (ARIAD PASS TM) program. Iclusig is a treatment for adult patients with refractory chronic myeloid leukemia or Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia.

The decision by ARIAD to utilize a closed distribution network with Biologics was made to ensure a high-touch care model for patients on Iclusig and to increase efficiencies as the product is made commercially available in the U.S. this month.

“We believe Biologics’ approach to patient care and expertise within oncology will deliver the best value and experience to our patients and providers,” said Marty J. Duvall, executive vice president and chief commercial officer at ARIAD. “Our primary objective is to make sure that our patients can access, afford and adhere to this important cancer medicine.”

In addition to providing pharmacy services and supporting the ARIAD PASS program, Biologics will help transition patients from the Iclusig single-patient Investigational New Drug (sIND) program to commercial or patient assistance product offerings. Biologics will also manage ARIAD’s patient assistance and co-pay support programs by conducting benefits investigations and prior authorizations to assess and assist with patient eligibility.

“We’re thrilled to be selected by ARIAD as the exclusive integrated channel partner for Iclusig,” said Dan Duffy, chief business development officer at Biologics. “We share the same goal of making sure patients receive the best care on Iclusig and are dedicated to providing seamless execution.”

Iclusig will be available commercially in the U.S. this month. For more information on Iclusig, please visit www.iclusig.com. For more information on the ARIAD PASS program, patients and physicians should call the U.S. toll-free phone number 1-855-447-PASS (7277).

About Iclusig ® (ponatinib)

Iclusig is a kinase inhibitor. The primary target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using ARIAD’s computational and structure-based drug design platform specifically to inhibit the activity of BCR-ABL. Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, a mutation which has been associated with resistance to other approved TKIs.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,160.84 +102.49 0.64%
S&P 500 1,923.74 +9.89 0.52%
NASDAQ 4,668.1440 +32.0390 0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs